Aptamers

Aptamers: Tiny Molecules, Huge Potential

Aptamers: Tiny Molecules, Huge Potential

Aptamers: Tiny Molecules, Huge Potential

Aptamers: Tiny Molecules, Huge Potential

Aptamers were first discovered in the early 90s, and have since been the focus of extensive research. These unique, single-stranded DNA or RNA molecules bind specifically to target molecules, revolutionizing therapeutics and diagnostics.

This tiny wonder offers numerous advantages due to their small size, stability, and ability to target various molecules, making them the perfect alternative to antibodies in several applications.

Milestones in Aptamer Research

1990

Aptamers First Discovered

Aptamers First Discovered

Aptamers First Discovered

Aptamers First Discovered

2001

Macugen: First FDA-Approved Aptamer Drug

Macugen: First FDA-Approved Aptamer Drug

Macugen: First FDA-Approved Aptamer Drug

Macugen: First FDA-Approved Aptamer Drug

2010

NOX-A12: Aptamer in Cancer Therapy

NOX-A12: Aptamer in Cancer Therapy

NOX-A12: Aptamer in Cancer Therapy

NOX-A12: Aptamer in Cancer Therapy

2020

Aptamers in COVID-19 Diagnostics

Aptamers in COVID-19 Diagnostics

Aptamers in COVID-19 Diagnostics

Aptamers in COVID-19 Diagnostics

Aptamers in Action

Aptamers in Action

Explore the fascinating world of aptamers and their far-reaching impact on diagnostics, therapeutics, and research, from cancer to COVID-19.

© 2023 Aptamers Literature, All Rights Reserved

© 2023 Aptamers Literature, All Rights Reserved